Reviewer ’s report  
 
Title: Non-steroidal anti -inflammatory drug -induced enteropathy a s a major risk factor for small 
bowel bleeding: A retr ospective study  
 
Version: 1 Date: 07 May 2020  
 
Reviewer: Huseyin Alkim  
 
Reviewer's report:  
 
First of all, I should mention that this article is a revised article. However, the original version of 
this article was not seen and evaluated by me.  
 
Secondly, when I look at the photos in figure 1B, 1C, 1D and 1E it is not poss ible to say whether 
any of these images are not compatible with Crohn's disease. Therefore, it is not possible to 
classify these lesions (1D and 1E) as NSAID -related ulcers only by looking at these images and 
the patient's history of aspirin / NSAID use.  
 
Thirdly, If you are going to give the percentage of a lesion or disease, you give the percentage 
according to the entire (whole) group, not just the group with positive findings: ie 25 of 60 is 
wrong.  
 
As a result, more detailed evaluation of capsule endosco pies of these patients is required. I think 
that without long term clinical follow -up, or capsule endoscopy repetttion after NSAID 
discontinuation, or histopathological evaluation it is not possible to classify these lesions as 
NSAID related lesions.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
No 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
No 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
No 
 
Are you able to assess any statistics in the  manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of writ ten English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1.  Have you in the past five years received reim bursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the future?  
 
2.  Do you hold any stocks or shares in an organisation that may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents  relating to the content 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary fro m an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have  no competing interests' 
below. If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests.  
 
Reviewer Publication Consent. I agree for my report to be made  available under an Open 
Access Creative Commons CC -BY License ( http://creativecommons.org/licenses/by/4.0 ) if thi s 
manuscript is accepted for publication. Any comments that I do not wish to be included in the 
published report have been included as confidential comments to the editor,  which will not be 
published.  If you are not happy for us to publish this report, please contact the edi torial office 
before completing the review.  If you wish, you can include your name in your published report. 
Please no te you must decide whether to include your name at the start of the process and  confirm 
this decision whenever prompted. If you change your decision later, we will not be able to 
publish your name.  
 
I agree to the terms of the CC -BY 4.0 license; please publ ish my name with my report.  
Reviewer ’s report  
 
Title: Non-steroidal anti -inflammatory drug -induced enteropathy a s a major risk factor for small 
bowel bleeding: A retr ospective study  
 
Version: 1 Date: 07 May 2020  
 
Reviewer: Huseyin Alkim  
 
Reviewer's report:  
 
First of all, I should mention that this article is a revised article. However, the original version of 
this article was not seen and evaluated by me.  
 
Secondly, when I look at the photos in figure 1B, 1C, 1D and 1E it is not poss ible to say whether 
any of these images are not compatible with Crohn's disease. Therefore, it is not possible to 
classify these lesions (1D and 1E) as NSAID -related ulcers only by looking at these images and 
the patient's history of aspirin / NSAID use.  
 
Thirdly, If you are going to give the percentage of a lesion or disease, you give the percentage 
according to the entire (whole) group, not just the group with positive findings: ie 25 of 60 is 
wrong.  
 
As a result, more detailed evaluation of capsule endosco pies of these patients is required. I think 
that without long term clinical follow -up, or capsule endoscopy repetttion after NSAID 
discontinuation, or histopathological evaluation it is not possible to classify these lesions as 
NSAID related lesions.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
No 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
No 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
No 
 
Are you able to assess any statistics in the  manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of writ ten English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1.  Have you in the past five years received reim bursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the future?  
 
2.  Do you hold any stocks or shares in an organisation that may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents  relating to the content 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary fro m an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have  no competing interests' 
below. If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests.  
 
Reviewer Publication Consent. I agree for my report to be made  available under an Open 
Access Creative Commons CC -BY License ( http://creativecommons.org/licenses/by/4.0 ) if thi s 
manuscript is accepted for publication. Any comments that I do not wish to be included in the 
published report have been included as confidential comments to the editor,  which will not be 
published.  If you are not happy for us to publish this report, please contact the edi torial office 
before completing the review.  If you wish, you can include your name in your published report. 
Please no te you must decide whether to include your name at the start of the process and  confirm 
this decision whenever prompted. If you change your decision later, we will not be able to 
publish your name.  
 
I agree to the terms of the CC -BY 4.0 license; please publ ish my name with my report.  
Please review this paper.
user
Reviewer ’s report  
 
Title: Non-steroidal anti -inflammatory drug -induced enteropathy a s a major risk factor for small 
bowel bleeding: A retr ospective study  
 
Version: 1 Date: 07 May 2020  
 
Reviewer: Huseyin Alkim  
 
Reviewer's report:  
 
First of all, I should mention that this article is a revised article. However, the original version of 
this article was not seen and evaluated by me.  
 
Secondly, when I look at the photos in figure 1B, 1C, 1D and 1E it is not poss ible to say whether 
any of these images are not compatible with Crohn's disease. Therefore, it is not possible to 
classify these lesions (1D and 1E) as NSAID -related ulcers only by looking at these images and 
the patient's history of aspirin / NSAID use.  
 
Thirdly, If you are going to give the percentage of a lesion or disease, you give the percentage 
according to the entire (whole) group, not just the group with positive findings: ie 25 of 60 is 
wrong.  
 
As a result, more detailed evaluation of capsule endosco pies of these patients is required. I think 
that without long term clinical follow -up, or capsule endoscopy repetttion after NSAID 
discontinuation, or histopathological evaluation it is not possible to classify these lesions as 
NSAID related lesions.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
No 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
No 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
No 
 
Are you able to assess any statistics in the  manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of writ ten English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1.  Have you in the past five years received reim bursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the future?  
 
2.  Do you hold any stocks or shares in an organisation that may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents  relating to the content 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary fro m an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have  no competing interests' 
below. If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests.  
 
Reviewer Publication Consent. I agree for my report to be made  available under an Open 
Access Creative Commons CC -BY License ( http://creativecommons.org/licenses/by/4.0 ) if thi s 
manuscript is accepted for publication. Any comments that I do not wish to be included in the 
published report have been included as confidential comments to the editor,  which will not be 
published.  If you are not happy for us to publish this report, please contact the edi torial office 
before completing the review.  If you wish, you can include your name in your published report. 
Please no te you must decide whether to include your name at the start of the process and  confirm 
this decision whenever prompted. If you change your decision later, we will not be able to 
publish your name.  
 
I agree to the terms of the CC -BY 4.0 license; please publ ish my name with my report.  
assistant